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A B S T R A C T
Purpose: Early assessment of tumour response to treatment with repeated FDG-PET-CT imaging has potential for
treatment adaptation but it is unclear what the optimal time window for this evaluation is. Previous studies
indicate that changes in SUVmean and the effective radiosensitivity (αeff, accounting for uptake variations and
accumulated dose until the second FDG-PET-CT scan) are predictive of 2-year overall survival (OS) when
imaging is performed before radiotherapy and during the second week. This study aims to investigate if multiple
FDG-PET-derived quantities determined during the third treatment week have stronger predictive power.
Methods: Twenty-eight lung cancer patients were imaged with FDG-PET-CT before radiotherapy (PET1) and
during the third week (PET2). SUVmean, SUVmax, SUVpeak, MTV41%–50% (Metabolic Tumour Volume),
TLG41%–50% (Total Lesion Glycolysis) in PET1 and PET2 and their change (), as well as average αeff (αeff ) and
the negative fraction of αeff values <f( αeff 0) were determined. Correlations were sought between FDG-PET-de-
rived quantities and OS with ROC analysis.
Results: Neither SUVmean, SUVmax, SUVpeak in PET1 and PET2 (AUC=0.5–0.6), nor their changes
(AUC=0.5–0.6) were significant for outcome prediction purposes. Lack of correlation with OS was also found
for αeff (AUC=0.5) and <fαeff 0 (AUC=0.5). Threshold-based quantities (MTV41%–50%, TLG41%–50%) and
their changes had AUC=0.5–0.7.
P-values were in all cases ≫0.05.
Conclusions: The poor OS predictive power of the quantities determined from repeated FDG-PET-CT images
indicates that the third week of treatment might not be suitable for treatment response assessment.
Comparatively, the second week during the treatment appears to be a better time window.
1. Introduction
The development and the clinical implementation of functional and
molecular imaging during the last decades, together with sustained
research work and innovations in imaging segmentation, registration
and fusion, have imposed repeated imaging as one of the most pro-
mising tools for treatment response assessment [1]. The identification
of predictive factors for tumour responsiveness at an early stage is
fundamental for cancer treatment adaptation and individualisation. A
patient-specific treatment adaptation, possibly through a dose escala-
tion in the most radioresistant regions for the poor responders at risk of
local recurrence, could improve treatment results [2–5]. 18F-fluor-
odeoxy-D-glucose Positron Emission Tomography and Computed To-
mography (FDG-PET-CT) have a great impact on cancer detection,
staging, and treatment outcome assessment in a broad range of tumour
types [6–8]. For lung cancer, several studies have already explored the
possibility of identifying universal criteria for tumour responsiveness to
chemoradiotherapy or radiotherapy alone from FDG-PET imaging
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acquired after the completion of the treatment [9–12]. However, a
limited number of investigations have so far accounted for changes in
specific parameters at an early stage of chemoradiotherapy [13–17].
Recently, two independent studies on the same Non-Small Cell Lung
Cancer (NSCLC) patient cohort have shown that different quantities can
be calculated and were predictive of 2-year overall survival (OS) when
imaging was performed before radiotherapy and during the second
week [18,19]. Van Elmpt et al. [18] studied the change in the metabolic
activity of the tumour based on the difference between the mean
Standard Uptake Value (SUV), while Toma-Dasu et al. [19] adopted a
volumetric approach and stratified the patients in good and poor re-
sponders based on calculations of an operational parameter, the effec-
tive radiosensitivity (αeff).
In the assessment of the tumour response to treatment with repeated
FDG-PET-CT imaging, the identification of the optimal window to
performing the FDG-PET-CT scan during treatment is still unclear and
few studies exist on the topic [20,21]. The time lapse between the first
and the second FDG-PET-CT scan should be compatible with in-
dividualized treatment adaptation and should be carefully selected so
that clonogenic cells are still detectable but the FDG-PET response is not
affected to a large extent by the inflammatory reactions following
chemoradiotherapy [22]. It could be hypothesised that the third week
during the treatment might have a stronger predictive power on
treatment outcome as compared to the second week since a larger
portion of clonogenic cells has been depleted and therefore larger
variations in the radiotracer uptake with respect to the initial FDG-PET
image might be expected. At the same time, however, radiation induced
inflammation might introduce a bias in the assessment of the uptake
variation.
The present study therefore aims at assessing whether the third
week of treatment could be a suitable time window for the assessment
of tumour responsiveness as a predictor for the treatment outcome. In
particular, parameters related to the distributions of αeff values were for
the first time tested for robustness of outcome prediction with respect to
time window.
2. Materials and methods
2.1. Treatment protocol and PET-CT acquisition
Twenty-eight patients with advanced stage (stage III and IV) of
NSCLC (10 adenocarcinoma cases, 9 squamous cell carcinoma cases,
and 9 non-otherwise specified cases) were treated with concomitant
chemoradiotherapy at the Maastricht University Medical Center (The
Netherlands) between 2011 and 2012 and were analysed in this study.
Patients enrolled in the clinical trial (NTC00522639 at clinical-
trials.gov) had no surgery and no previous cancer within five years
prior to diagnosis. The administered chemotherapy agent was carbo-
platin-gemcitabine. The radiotherapy treatment consisted of two con-
secutive regimens of photon IMRT (Intensity Modulated
RadioTherapy): a dose of 45 Gy was delivered in 1.5 Gy fractions twice
per day followed by a dose-escalation up to 69 Gy in 2 Gy daily frac-
tions.
The Xio/Focal System (Computerized Medical Systems, St. Louis,
MO, USA) was used for radiotherapy planning. The software makes use
of a convolution-superposition algorithm with inhomogeneity correc-
tions. ICRU 50 [23] guidelines were adopted for treatment planning.
The primary Gross Tumour Volume (GTVprim) was delineated on
fused FDG-PET-CT images by experienced radiation oncologists.
Patients were imaged in radiotherapy position with FDG-PET-CT
before the treatment and during the third week of radiotherapy. The
mean and median time interval between the first FDG-PET-CT acqui-
sition and the start of radiotherapy were equal to 11 and 10 days, re-
spectively; while the mean and median time interval between the first
and second FDG-PET-CT scan were both equal to 23 days.
The FDG-PET-CT acquisitions were performed with a Siemens
Truepoint 40 camera (Siemens AG, Munich, Germany) in radiotherapy
position. Patients fasted for at least 6 h before scanning and the
NEDPAS [24] protocol was used with a FDG activity in MBq equal to
2.5 times the body weight in kg injected intravenously. FDG-PET image
reconstruction was performed using an Ordered Subset Expectation
Table 1
Characteristics of the Non-Small Cell Lung Cancer (NSCLC) patients in the study. Information on the age, gender, and sex of the patients are reported together with the histology of the
tumour, number of days between the first PET scan (PET1) and the second PET scan (PET2), number of days between the start of radiotherapy (RT) and PET2, number of fractions (fx)
delivered by the time of PET2, dose delivered until PET2, and overall survival (OS) at 2 years (2Y) follow-up (1= survivor, 0=non-survivor).
# Age Gender Weight Histology Days between PET1 and PET2 Days between start of RT and PET2 Fx at PET2 Dose at PET2 (Gy) OS at 2Y
1 53 F 64 Adeno 22 12 24 36 0
2 48 F 65 Adeno 24 13 26 39 1
3 58 F 48.5 Adeno 24 12 24 36 0
4 59 F 60 Squam 22 12 24 36 1
5 63 M 84 Squam 21 12 24 36 0
6 49 M 70 Squam 21 12 24 36 1
7 67 F 78 Adeno 31 14 28 42 0
8 59 F 54 Other 23 13 26 39 1
9 66 M 66 Squam 21 12 24 36 1
10 70 M 93 Other 23 13 26 39 0
11 68 M 84 Adeno 25 12 24 36 0
12 56 M 80 Other 27 15 30 45 1
13 71 M 83 Other 21 12 24 36 1
14 78 F 63 Other 22 12 24 36 1
15 60 M 79 Squam 21 12 24 36 1
16 55 F 91 Adeno 26 14 28 42 0
17 66 M 78 Squam 20 12 24 36 1
18 66 F 50 Other 21 12 24 36 1
19 64 M 103 Squam 22 12 24 36 0
20 59 F 61 Other 23 13 26 39 0
21 67 F 65 Adeno 25 12 24 36 1
22 64 M 81 Other 21 12 24 36 1
23 71 F 64 Other 23 14 28 42 0
24 58 F 68 Squam 28 15 30 45 1
25 38 F 47 Adeno 21 9 18 27 1
26 86 M 59 Squam 23 12 24 36 1
27 52 M 78 Adeno 25 12 24 36 1
28 69 F 74 Adeno 22 12 24 36 0
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Maximization 2D four iterations eight subsets (OSEM2D 4i8s) algo-
rithm. Corrections for random events and decay were applied, as well as
scattering corrections using model-based methods. FDG-PET scans were
also corrected for attenuation either using the mid-ventilation phase of
the 4D-CT or a 3D-CT thorax. FDG-PET-CT scans were performed as
static studies. No special breathing instructions were given to the pa-
tients, but normal breathing was recommended. CT and FDG-PET image
voxel sizes were respectively equal to (0.098×0.098×0.3) cm3 and
(0.407×0.407× 0.3) cm3. Additional information on patient data,
treatment protocol, and image data acquisition are described in Ref.
[25].
Treatment outcome in terms of OS at 2 years was available for all
the patients in the ensemble. Seventeen patients were alive at two years.
The patient characteristics most relevant for the presented analysis
are listed in Table 1.
2.2. Image registration and image analysis
FDG-PET-CT scans acquired at the two successive time points were
imported and co-registered in a research version of the treatment
planning system RayStation version 4.6.100.4 (RaySearch Laboratories
AB). Specifically, the two CT images, inherently registered to the FDG-
PET scans, were co-registered to achieve a voxel-to-voxel correlation
between the two corresponding FDG-PET images. The registration
consisted of a rigid registration based on bony anatomy followed by a
hybrid deformable registration. The latter combines image information
with anatomical information as provided by contoured image sets and
uses as controlling region the external patient contour aiming at ana-
tomical structure integrity [26].
Co-registered FDG-PET images were exported from the RayStation
and analysed with an in-house MatLab code (The MathWorks Inc.,
Natick, MA, version R2011b) able to handle FDG-PET-CT images, dose
distribution and delineated structures outside RayStation as well as to
calculate the quantities of interest to perform the rest of the analysis.
2.3. Calculation of FDG-PET-related quantities of interest
To assess tumour early responsiveness to the treatment, a systematic
voxel-based analysis using the co-registered FDG-PET images taken
before radiotherapy and during the third week in the primary gross
tumour volume (GTVprim) was performed. The method, developed by
Toma-Dasu et al. [19], takes into account the local uptake changes in
the target volume of the paired FDG-PET images and the planned ac-
cumulated dose distribution at the second FDG-PET acquisition. The
algorithm assumes that the uptake variation at voxel level in the images
is proportional to the variation of functional clonogenic cell density and
it is based on the Linear Quadratic (LQ) [27] formalism for cell killing.
The same radiosensitivity to fractionation (i.e. =α β/ 10 Gy for the tu-
mour) is assumed for all the patients and an operational parameter, the
effective radiosensitivity αeff, is calculated:
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where PETi,1 and PETi,2 are the SUV values in the FDG-PET images for
the voxel of interest i acquired before and during radiotherapy, re-
spectively; di and n are the planned dose per fraction and the number of
fractions delivered until the second FDG-PET image, respectively.
A positive value of the effective radiosensitivity parameter indicates
a decrease in the tracer uptake of the FDG-PET scan acquired during the
treatment with respect to the initial FDG-PET scan for a certain voxel
under consideration and a negative value indicates an increase, re-
spectively.
The distribution of the effective radiosensitivity, αeff, in each voxel
in a volume of interest is therefore obtained. The average value of the
effective radiosensitivity, αeff , and the fraction of negative values of αeff,
<fα 0eff , are also calculated. The volume of interest in this study in which
the distribution of the effective radiosensitivity was assessed was
GTVprim.
Fig. 1. Schematic illustration of the tumour response assessment method. Two [18F]-fluorodeoxy-D-glucose positron emission tomography images taken before (a) and during the third
week of treatment (b), and the accumulated dose distribution calculated by summing up the planned doses for each fraction delivered up to the second scan (c) are used to calculate a
voxel-based effective radiosensitivity (d) and, thus, assess the responsiveness of the tumour to radiotherapy.
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A schematic illustration of the method for assessing the early tu-
mour responsiveness to treatment is presented in Fig. 1.
Additionally, other FDG-PET-derived quantities were also scored in
the first and second FDG-PET scan. The mean and the maximum SUV
values (SUVmean, SUVmax) in the first and second FDG-PET scan were
scored in the volume corresponding to GTVprim. Following the
European Association of Nuclear Medicine (EANM) guidelines for tu-
mour imaging with FDG-PET-CT (version 2.0, [28]), SUVpeak was
scored in a 1.2 cm diameter spherical volume of interest (VOI) posi-
tioned such that the average value across all positions within the lesion
is maximised. Threshold-based quantities such as the Metabolic Tumour
Volume (MTV) and the corresponding Total Lesion Glycolysis (TLG)
were also considered in the study. The MTV41% and MTV50% corre-
sponded, respectively, to a 3D isocontour at 41% of the maximum pixel
value and to a 3D isocontour at 50% of the maximum pixel value [28].
The TLG values (TLG41% and TLG50%, respectively) were obtained as
the product of the mean SUV value in the MTV VOI and the MTV vo-
lume (MTV41% and MTV50%, respectively) [28].
The percent change in the maximum SUV (ΔSUVmax) within GTVprim
between the FDG-PET scans before the treatment (SUVmax,1) and during
the third week (SUVmax,2) was calculated as ΔSUVmax= 100
(SUVmax,1− SUVmax,2)/SUVmax,1. Similarly, the percent changes in the
other FDG-PET-derived quantities mentioned above (ΔSUVmean,
ΔSUVpeak, ΔMTV41%, ΔMTV50%, ΔTLG41%, and ΔTLG50%) were
calculated.
2.4. Statistical analysis
The statistical analysis was performed by using the Receiver
Operating Characteristic (ROC) method to seek for correlations be-
tween the treatment outcome of NSCLC patients, expressed as 2-year
OS, and the quantities of interest mentioned above (αeff , <fα 0eff ,
SUVmax, SUVmean, SUVpeak, MTV41%, MTV50%, TLG41% and TLG50%
in PET1 and PET2, the percentage change of SUVmean, SUVmax, SUVpeak,
MTV41%, MTV50%, TLG 41% and TLG50%). The Area Under the ROC
curve (AUC) and corresponding p-values were scored. A p-value below
0.05 was considered statistically significant.
The commercial software, MedCalc, version 13.1.0.0 (MedCalc
Software, Ostend, Belgium) was used for the calculations.
3. Results
Fig. 2 shows the distribution of the percent change in the FDG-PET-
derived quantities analysed in the study (SUVmean, SUVmax, SUVpeak,
MTV41%, MTV50%, TLG 41% and TLG50%), together with the dis-
tributions of αeff and <fα 0eff for the NSCLC cohort under investigation.
Patients were divided based on the 2-year OS as survivors and non-
survivors. As seen, the distribution of the data is similar for survivors
(black) and non-survivors (red) in all cases, as evidenced also by the
similar median and mean values of the distributions (empty square and
horizontal line, respectively, in the box plot).
Fig. 3 shows the ROC curves investigating the correlation between
all the FDG-PET-derived quantities under analysis in this study and the
treatment outcome. As reasonably expected from the results shown in
Fig. 2, the ROC analysis indicates that none of the considered quantities
has a statistically significant discriminant power. AUC values for αeff
and <fα 0eff were, respectively, AUC=0.5 with p= 0.7 and AUC=0.5
with p=0.8. The change between the FDG-PET uptake in PET1 and
PET2 did not correlate with the outcome either and resulted in an
AUC=0.6 with p=0.3 for ΔSUVmax, AUC=0.5 with p=0.7 for
ΔSUVmean, and AUC=0.6 with p=0.4 for ΔSUVpeak. Similar results
are also found for the SUVmax, SUVmean, and SUVpeak values in PET1 or
PET2 having all AUC values in the range 0.5–0.6 with p-values between
0.5 and 0.9.
Threshold-based methods (MTV41%, MTV50%, TLG41%, and
TLG50%) calculated in PET1 and PET2 did not result in better pre-
dictive power either with an AUC value range equal to 0.5–0.7 and p-
values in the range 0.2–0.7. Percentage difference of the mentioned
threshold-based quantities, i.e. ΔMTV41%, ΔMTV50%, ΔTLG41%, and
ΔTLG50%, had AUC values respectively equal to 0.7 (p=0.1), 0.6
(p= 0.2), 0.6 (p= 0.5), and 0.6 (p= 0.3).
4. Discussion
One of the most quoted reasons of concern when assessing the re-
sponse to treatment of patients receiving chemoradiotherapy based on
repeated FDG-PET-CT imaging at different time points during the
course of the treatment is related to the possibility of quantifying the
metrics used in the comparison in an artefact-free manner [20,22].
Thus, the potentially radiation-induced image misrepresentations due
to, for example, tissue inflammations and the way they might affect the
results should be taken into account. The feasibility of designing me-
trics based on significant changes in the SUV values at different time
points during the course of chemoradiotherapy for NSCLC patients has
been shown in the study by Edet-Sanson et al. [20]. The authors aimed
at verifying whether significant changes in the uptake of FDG or in the
volumes defined based on the tracer uptake could be determined at
different points during the course of a conventionally fractionated
radiotherapy treatment, early enough to allow treatment adaptation.
They performed 5–6 FDG-PET-CT scans, one every 7 fractions of 2 Gy,
during the course of the treatment for 10 NSCLC patients. Their results
lead to the conclusion that although the normalised SUVmax determined
at different time points within the treatment could be determined in a
radiation-induced misrepresentation-free manner, other parameters,
depending on the size of the volume delineated using FDG-PET-based
thresholds, were not reliable after about one to two weeks. However,
this study did not include in the analysis the correlation between the
tracer uptake and the treatment outcome. A prospective subsequent
study by the same group, investigated the potential of using FDG-PET-
based metrics and their changes during chemoradiotherapy as pre-
dictive factors for the treatment outcome at 1 year, expressed as OS or
tumour progression [21]. The first FDG-PET image was acquired right
before the start of the radiotherapy and the second image five weeks
within the treatment after the delivery of 40–45 Gy. They concluded
that the only parameter that was actually able to predict the outcome at
1 year was SUVmax in the second FDG-PET image taken at 5 weeks after
the start of the treatment. Furthermore, Vera et al. [21] showed that the
fixed threshold methods, based on FGD uptake, such as 40% SUVmax,
tend to delineate larger volumes even when the lesions were obviously
decreasing at visual examination. It seems plausible to hypothesize that
radiation-induced inflammation or similar processes is the reason for
this increase in size. To some extent, the present and the above de-
scribed studies point to the similar conclusion that beyond 1–2weeks
within the treatment the delineation of volumes based on FDG-PET
becomes problematic. Consequently, the derivation of related para-
meters, such as SUVmean and its changes, becomes unreliable and leads
to poor correlation with the treatment outcome with the exception just
mentioned (i.e. SUVmax at 5 weeks during the treatment). Nonetheless,
a direct comparison between the findings of our study and the one by
Vera et al. [21] is not entirely relevant because of the non-identical
manner in which the analysed parameters were derived. The predictive
value of repeated FDG-PET-CT for the treatment outcome for NSCLC
patients was also investigated in a recent study by Mattoli et al. [29]
concluding that early metabolic response was predictive for local con-
trol, progression free survival and overall survival after low-dose frac-
tionated radiotherapy with concurrent chemotherapy. However, a di-
rect comparison of the findings of the study by Mattoli et al. and the
present one is not possible due to the different treatment regimens
employed for the patient cohorts in the two studies.
The analysis of the tumour responsiveness performed in this study
based on the effective radiation sensitivity, αeff, did not lead to better
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predictions of the treatment outcome either, although it is not de-
pending on a volume delineated based on FDG-PET uptake but strictly
determined within the GTVprim. Beyond the possible radiation-induced
inflammation problem, one possible explanation for this result is the
actual definition of the effective radiation sensitivity. In fact, αeff im-
plicitly assumes that the decrease in the FDG tracer uptake implies ef-
fective cell killing and an increase in the FDG uptake indicates that cell
proliferation has a larger effect than treatment induced cell depletion.
However, one has to keep in mind that the signal in the image is not
given only by the surviving cells that metabolise the tracer but also by
the damaged cells which are doomed to die but are still viable at the
time of the scan and still capable of metabolising the tracer [22]. The
proportion of the surviving clonogens in the entire cell population in
the target, including the damaged clonogens doomed to die, varies at
different moments during the treatment and therefore the dis-
criminatory power of a metric for tumour response based on this is also
expected not to be the same at different time points during the treat-
ment.
The approach based on repeated examinations performed for the
same patient in order to determine the effective radiation sensitivity,
αeff, provides however one strong advantage. By using each patient as
its own reference, no specific assumptions regarding the radio-
sensitivity of the patient would be required. In addition, according to
the assumed approach for calculation of the αeff distributions, each
voxel is its own reference and this avoids adding to the analysis un-
necessary uncertainties associated with making specific assumptions
regarding the initial cell density or proliferation rates in the voxels or
possible causes for persistent uptake in the voxels. Uncertainties de-
riving from, for example, the limited resolution of the PET images and
partial volume effects are also expected to be less pronounced. No
specific strategy at the moment of the image acquisition was adopted to
reduce the motion due breathing of the patient (except for normal
breathing recommendation) under the assumption that the possible
blurring of the PET images would be overpassed by uncertainties re-
lated to the co-registration of images (FDG-PET-CT1 and FDG-PET-
CT2).
The algorithm connected with the hybrid deformable registration
was extensively tested and validated and found to perform well in
comparisons to other algorithms, as discussed in Ref. [26]. The method
for calculation of αeff distributions was also tested for robustness by
intentionally perturbing the registration between the FDG-PET images
in Ref. [19]. Rigid 5mm translations in anterior-posterior, left-right,
and cranial-caudal directions were respectively introduced in the re-
gistration matrix. The classification of patients in responders and non-
responders to treatment resulted to be robust against the performed
perturbation [19].
A limitation of the present study is represented by the relatively low
number of patients (N=28). Unfortunately, this is a common problem
in this kind of investigations (e.g. N= 34 in Van Elmpt et al. [18],
N= 26 in Toma-Dasu et al. [19], and N=10 in Edet-Sanson et al.
[20]). Needless to say that the study would benefit from being repeated
on a larger number of patients. In event of a positive correlation be-
tween the tumour responsiveness metrics and the treatment outcome, a
cross-validation would have to be performed as in the previous study by
Toma-Dasu et al. [19] on a similar number of patients imaged at
2 weeks from the start of the treatment but here it was not the case. So,
one could only conclude from the current analysis that FDG-PET ima-
ging at three weeks into treatment does not give any prognostic/pre-
dictive value for this dataset.
In summary, the lack of correlation of SUVmax, SUVmean, SUVpeak,
MTV41%, MTV50%, TLG41%, and TLG50% and their percent changes
between the FDG-PET scans before the treatment and during the third
week with OS indicates that the third week of treatment might not be
suitable for assessing the responsiveness to treatment and subsequent
Fig. 2. Box plots of the distribution of PET-derived quantities of interest. Data are shown separately for survivors (black) and non-survivors (red). The horizontal line in the box indicates
the median value of the data, and the small square indicates the mean value of the distribution. The box plot whiskers indicate scores outside the middle 50%. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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treatment adaptation. In addition, the lack of correlation between the
parameters derived from the distribution of the calculated effective
radiosensitivity at three weeks from the start of the treatment with the
treatment outcome points towards the same conclusion. Comparing
with previous similar studies, the second week during the treatment
appears to be a better time window for response assessment.
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